**Background**

**ANG1005** is a novel, targeted taxane derivative and gains entry into the tumor cells through the LRP pathway to cross the BBB and demonstrates an overall treatment response; or 2) were dosed at the MTD and received at least two treatment cycles.

**Methods**

**Phase I: Solid tumor with progressive brain metastases (ANG1005-CLN-02)**

- Multi-center, open-label, single arm study with escalating doses (650 mg/m² & 700 mg/m²);
- 80 patients enrolled (70 patients at 650 mg/m² & 10 patients at 650 mg/m²);
- Patients with NSCLC and indicated progressive disease at brain metastases; or 2) were dosed at the MTD and received at least two treatment cycles.

**Phase II: HER2+ breast cancer patients with brain metastases (ANG1005B016)**

- Multi-center, open-label, single arm study with escalating doses (550 mg/m²);
- 80 patients enrolled (70 patients at 650 mg/m² & 10 patients at 650 mg/m²);
- Patients with HER2+ breast cancer; or 2) were dosed at the MTD and received at least two treatment cycles.

**Anti-Tumor Activity**

**Case Study #1: 55 y.o. female with metastases originating from HER2+ Breast Cancer**

- Initial treatment: Carboplatin (AUC 5) + Paclitaxel (175 mg/m²) every 3 weeks for 6 cycles.
- Disease progressed: Ascites, 20% improvement, TTP 7 months.

**Case Study #2: 50 y.o. female with brain metastases originating from HER2+ Breast Cancer**

- Initial treatment: Carboplatin (AUC 5) + Paclitaxel (175 mg/m²) every 3 weeks for 6 cycles.
- Disease progressed: Brain metastases, PR 100%, TTP 18 months.

**Case Study #3: 55 y.o. female with metastases originating from HER2+ Breast Cancer**

- Initial treatment: Carboplatin (AUC 5) + Paclitaxel (175 mg/m²) every 3 weeks for 6 cycles.
- Disease progressed: Brain metastases, SD 12 months, TTP 18 months.

**Side Effects**

- Fatigue
- Nausea
- Diarrhea
- Hair loss
- Grade ≥3 Thrombocytopenia

**Conclusion**

**ANG1005** demonstrated CNS anti-tumor activity and **ANG1005** also demonstrated peripheral anti-tumor activity, providing additional patient benefit.

**Acknowledgement**

All of the patients, caregivers and staff who have participated in these studies.

**Authors**


**Corresponding Authors**

Nancy U. Lin, PhD, M.D., Associate Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; E-mail: Nancy.Lin@nih.gov